Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are chronic immunoinflammatory diseases of unknown etiology, which are characterized by inflammatory destructive damage to the intestinal wall and a chronic relapsing course involving systemic and extraintestinal complications1.
The originator investigational product BCD-261 is a monoclonal antibody being developed for the treatment of inflammatory bowel disease.
A monoclonal antibody is a protein created by scientists in the laboratory, similar to the immune system natural antibodies, designed to bind to a specific target in the human body2.
The target of the product under developed, BCD-261, is proinflammatory cytokine TL1A3, which has a negative effect on the Crohn's disease and ulcerative colitis4.
BCD-261 is one of the drug products in the clinical development program of BIOCAD.
- Knyazev O. V., Shkurko T. V., Kagramanova A. V., Veselov A. V., Nikonov E. L. Epidemiologiya vospalitel'nykh zabolevaniy kishechnika. Sovremennoye sostoyaniye problemy (obzor literatury). Dokazatel'naya gastroenterologiya. 2020;9(2):66 73.
- Weiner L. M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
- TL1A, TNF-like ligand 1A.
- Bamias G., Martin C., 3rd, Marini M., Hoang S., Mishina M., Ross W. G., et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171(9):4868-74.
This site section includes information about an unauthorized investigational drug product for human use.